الفهرس 
INTRODUCTION .Only 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
Hepatitis C virus (HCV) infection is a major global
health issue. The standard of care (SOC) therapy for HCV was combination
of pegylated interferon (PEG/IFN) and ribavirin (RBV). Almost all patients
treated with PEG/IFN and RBV experience one or more adverse events
during the course of therapy. Among these adverse effects is its affection on
hearing and vestibular system.